Compare Philip Morris International Inc. (PM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Repligen Corporation Common Stock — how do they compare? Philip Morris International Inc. trades at $206.58 (market cap $310.62B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Philip Morris International Inc. is far larger — about 27.9× Repligen Corporation Common Stock's market cap, and Philip Morris International Inc. pays a 3.21% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Philip Morris International Inc. for 85 Days and Repligen Corporation Common Stock for 0 Days on average.
| PM | RGEN | |
|---|---|---|
Market Cap | $310.62B | $11.14B |
Volume | 4,145,126 | 1,259,263 |
Sector | Consumer Staples | Health |
52-Week High | $205.58 | $194.57 |
52-Week Low | $144.33 | $102.87 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $353.73B | $11.02B |
Dividend Yield | 3.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $202.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $212.17. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.20, and maintains robust profitability with a net income margin of 25.56%. Recent news highlights growth in smoke-free products like IQOS and ZYN, now over 40% of revenue, and a raised 2026 EPS forecast due to favorable currency impacts.
The stock offers a compelling growth story driven by smoke-free product expansion and dividend reliability, but faces risks from regulatory pressures and high valuation multiples. With 68% of analysts rating it a Buy, upside exists toward the $225 high target, though investors should monitor debt levels and industry shifts.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
